The formulation produced a significant antigen presentation that activated CD8 + T lymphocytes, a prophylactic effect in preventing metastasis, and a high therapeutic effect in combination with checkpoint inhibitors in mice bearing B16-OVA tumor cells [82]. This evidence concerns the gene CD8A and neoplasm.